Leukotriene receptors as potential therapeutic targets
Takehiko Yokomizo,1 Motonao Nakamura,2 and Takao Shimizu3,4
1Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
2Department of Life Science, Graduate School of Science, Okayama University of Science, Okayama, Japan.
3Department of Lipidomics, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
4Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Address correspondence to: Takehiko Yokomizo, Department of Biochemistry, Graduate School of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 81.3.5802.1031; Email: yokomizo-tky@umin.ac.jp.
Find articles by
Yokomizo, T.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
2Department of Life Science, Graduate School of Science, Okayama University of Science, Okayama, Japan.
3Department of Lipidomics, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
4Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Address correspondence to: Takehiko Yokomizo, Department of Biochemistry, Graduate School of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 81.3.5802.1031; Email: yokomizo-tky@umin.ac.jp.
Find articles by Nakamura, M. in: JCI | PubMed | Google Scholar
1Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
2Department of Life Science, Graduate School of Science, Okayama University of Science, Okayama, Japan.
3Department of Lipidomics, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
4Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
Address correspondence to: Takehiko Yokomizo, Department of Biochemistry, Graduate School of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 81.3.5802.1031; Email: yokomizo-tky@umin.ac.jp.
Find articles by Shimizu, T. in: JCI | PubMed | Google Scholar
First published May 14, 2018 - More info
J Clin Invest. 2018;128(7):2691–2701. https://doi.org/10.1172/JCI97946.
Copyright © 2018, American Society for Clinical Investigation
Leukotrienes, a class of arachidonic acid–derived bioactive molecules, are known as mediators of allergic and inflammatory reactions and considered to be important drug targets. Although an inhibitor of leukotriene biosynthesis and antagonists of the cysteinyl leukotriene receptor are clinically used for bronchial asthma and allergic rhinitis, these medications were developed before the molecular identification of leukotriene receptors. Numerous studies using cloned leukotriene receptors and genetically engineered mice have unveiled new pathophysiological roles for leukotrienes. This Review covers the recent findings on leukotriene receptors to revisit them as new drug targets.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)